Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Effect of Intravenous Ferric Carboxymaltose on Death, Heart Failure Events, and Quality of Life in Iron Deficient Patients with Recent Myocardial Infarction Prevention of Cardiovascular Death, Heart Failure Events, and Quality of Life Decline with Ferric Carboxymaltose

Researchers are evaluating the effects of intravenous ferric carboxymaltose (FCM) compared to placebo in patients who recently experienced an acute myocardial infarction (AMI) and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled trial aims to assess whether FCM impacts mortality, heart failure events, serum NT-proBNP levels, and quality of life over a follow-up period of up to 36 months. The study specifically looks at the number and timing of heart failure events, changes in heart failure biomarkers, and quality of life using the EQ-5D questionnaire.

Age: 18Years - 90YearsAll GendersPhase 4
43 locations